Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

BIOCRYST I Form 4 July 08, 2011	PHARMACEU	ΓICALS I	NC								
FORM Check this if no longe subject to Section 16 Form 4 or Form 5 obligation may contin <i>See</i> Instruct 1(b).	s box er STATE 5. Filed pu s Section 17 ction	MENT O	Was F CHAN Section 10 Public Ut	hington, GES IN 1 SECUR 6(a) of the ility Hold	D.C. 205 BENEFI ITIES e Securition	49 C IAI es Ex pany	OW chang Act of	COMMISSION NERSHIP OF e Act of 1934, f 1935 or Section 40	OMB Number: Expires: Estimated a burden hou response	-	
(Print or Type Responses) 1. Name and Address of Reporting Person <u>*</u> STAAB THOMAS R II			2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 4505 EMPEI 200	(First) (ROR BLVD., S	Middle) UITE	3. Date of (Month/D 07/01/20	-	ansaction			Director X Officer (give below) Senior Vic		o Owner er (specify I CFO	
DURHAM, I	(Street) 4. If Amendr Filed(Month/I RHAM, NC 27703				-			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year) Execution any		3. Transactio Code (Instr. 8) Code V	on(A) or Dis (D) (Instr. 3, 4	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock (1)	07/01/2011			А	25,000	A	\$0	25,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount 2. 4. Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative Expiration Date Underlying Securitie (Month/Day/Year) (Instr. 3 and 4) Security or Exercise any Code Securities (Instr. 3) Price of (Month/Day/Year) (Instr. 8) Acquired (A) or Derivative Disposed of (D) Security (Instr. 3, 4, and 5) Amou Expiration Title Date Exercisable Numb Date Code V (D) (A) Shares Stock Option Common 07/01/2012(2) 07/01/2021 \$ 3.78 07/01/2011 200,000 200, Α (Right to Stock Buy)

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships							
I B	Director	10% Owner	Officer	Other				
STAAB THOMAS R II 4505 EMPEROR BLVD. SUITE 200 DURHAM, NC 27703			Senior Vice President and CFO					
Signatures								
/s/ Alane Barnes, by power of attorney		07/08/20)11					
**Signature of Reporting Person		Date						
Explanation of Responses:								

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted stock award. Will vest on the first anniversary of the date of grant, subject to continued employment on such vesting date.
- (2) Options become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.